Clinical trials: Thromboprophylaxis
Symptomatic Venous Thromboembolism (VTE)
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA).
- Trial name
- ROXI-ASPEN (NCT07213778)
- Testing
- REGN7508, Acetylsalicylic Acid (ASA)
- Where
- 51 sites in United States, Greece and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Thromboembolism, Arthroplasty Replacement, Knee
Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement.
- Trial name
- NCT00362492
- Testing
- Bilateral ultrasound examination 7+/- 2 after surgery
- Where
- 17 sites in France
- Volunteers
- 850 people
- Sponsor
- University Hospital, Caen
Thrombosis
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8…
- Trial name
- UNIVERSE (NCT02846532)
- Testing
- Rivaroxaban, Acetylsalicylic Acid
- Where
- 42 sites in United States, Argentina and 8 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Thromboembolism in the Puerperium
Safety of Fondaparinux as Post Partum Thromboprophylaxis
Venous thromboembolism (VTE) remains as one of leading causes of maternal morbidity and mortality, with postpartum period carries the greatest risk.
- Trial name
- NCT04447378
- Testing
- Fondaparinux 2.5Mg/0.5Ml Inj Syr
- Where
- Malaysia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Pancreatic Cancer, Thromboembolism
The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
This is a prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial to investigate the impact of thromboprophylaxis using innohep, beyond anticoagulation in the improvement of the clinical…
- Trial name
- imPaCT-PRO (NCT05178628)
- Testing
- Innohep, Chemotherapy: Gemcitabine + Nab-Paclitaxel
- Where
- 2 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Michalis Karamouzis
Venous Thromboembolism, Renal Impairment
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
This is a clinical trial including non-surgical patients, 70 years of age or older, with renal impairment requiring pharmacological venous thromboembolism prevention during hospitalization.
- Trial name
- NCT03158792
- Testing
- Enoxaparin 20Mg/0.2mL Prefilled Syringe, Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
- Where
- Lebanon
- Volunteers
- 32 people
- Sponsor
- Lebanese American University
Pregnancy Related, Antepartum DVT
Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)
This study is a randomized control trial to compare gestational age-based dosing with standard dosing of unfractionated heparin for thromboprophylaxis of hospitalized antepartum patients.
- Trial name
- NCT04635839
- Testing
- Standard Dose of Unfractionated Heparin, Gestational Age-Based Dose of Unfractionated Heparin
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Ovarian Cancer
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein thrombosis or pulmonary…
- Trial name
- NCT03532139
- Testing
- Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
IBD, Venous Thromboembolism
Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a relatively common disease that effects all age groups and carries significant morbidity and mortality.
- Conditions
- IBD, Venous Thromboembolism, Crohn Disease, Ulcerative Colitis
- Trial name
- EXPAND (NCT03935451)
- Testing
- Apixaban 2.5 milligram
- Where
- 2 sites in Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McMaster University
Healthy Volunteers
A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217)
In the course of the clinical study, the pharmacokinetics, pharmacodynamics, safety and tolerability of Dimolegin (DD217) 10 mg enteric-coated tablets after single administration to healthy volunteers at increasing doses were…
- Trial name
- NCT05181241
- Testing
- Dimolegin
- Where
- Russia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PharmaDiall Ltd.
Venous Thromboembolism
Electronic Strategies to Enhance Venous Thromboemboli (VTE) Prophylaxis in Hospitalized Medical Patients
Venous thromboemboli (VTE) are abnormal blood clots that commonly form in the blood vessels of the legs or lungs. They can block normal blood flow, damage organs, and even cause death.
- Trial name
- E-SENTRY (NCT01401725)
- Testing
- Electronic Order Entry System + CDSS, Electronic Order Entry System Only, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Acute Leukemia, Newly Diagnosed Acute Leukemia
Real World Assessment of Venous Thromboembolic Risk in Hospitalized Patients With Acute Leukemia
This is a observational study designed to identify risk factors for venous thromboembolism in patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
- Conditions
- Acute Leukemia, Newly Diagnosed Acute Leukemia, Thromboprophylaxis, Thromboprophylaxis in Acute Leukemia
- Trial name
- ReVeAL (NCT07831668)
- Volunteers
- 250 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Fetal Demise, Fetal Growth Restriction
Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
The risk of venous thromboembolism increases in pregnancy. Thrombophilia whether genetic or acquired, is a hypercoagulable disorder that may increase the risk of venous thromboembolic events.
- Conditions
- Fetal Demise, Fetal Growth Restriction, Preeclampsia, Abruptio Placentae
- Trial name
- NCT01068795
- Testing
- enoxaparin
- Where
- Israel
- Volunteers
- 144 people
- Sponsor
- HaEmek Medical Center, Israel
Lower Limb Injury, Pulmonary Embolism
Assessment of the Impact of TIP Score on Thromboprophylaxis in Patients With Non-surgical Lower Leg Trauma.
Traumatic lesions are the leading causes of admission to the emergency center (39%), isolated non-surgical lower limbs trauma are in the foreground.
- Conditions
- Lower Limb Injury, Pulmonary Embolism, Venous Thromboses
- Trial name
- EvaTIP (NCT03089255)
- Where
- France
- Volunteers
- 196 people
- Sponsor
- University Hospital, Angers
Pregnancy
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum
The risk of venous thromboembolism (VTE), which consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), increases during pregnancy and most strikingly in the postpartum period (6 weeks after delivery).
- Trial name
- PREFER-PP (NCT05318547)
- Testing
- standard-gamble technique, time trade-off technique
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Deep Vein Thrombosis, Pulmonary Embolism
Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology Patients
Prevention and Prophylaxis (Thromboprophylaxis - ACT) of Cancer Associated Thrombosis (CAT) in High Risk Oncology Patients: ACT4CAT.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Vena Cava Thrombosis, Iliac; Thrombosis
- Trial name
- NCT03909399
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Society of Medical Oncology
Thromboembolic Disease
Thromboprophylaxis by Low Molecular Heparin During the Post-partum Period
The purpose of this study is to determine the current level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol during the post-partum period.
- Trial name
- THROM-PP2021 (NCT04883385)
- Testing
- medical data collection
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Sud Francilien
Vascular Disease, Peripheral, Thromboprophylaxis
Heparin-Binding Protein and Heparins
Heparin-Binding protein is a protein from primary and secretory granluae of white blood cells. It is released when white blood cells become activated and has been advocated as a biomarker for sepsis.
- Conditions
- Vascular Disease, Peripheral, Thromboprophylaxis, Cardiovascular Diseases
- Trial name
- HepHep (NCT04146493)
- Testing
- Blood samples for Heparin-binding protein measurement
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Halla Halldorsdottir
Critical Illness
Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients
Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route of administration of LMWH for thromboprophylaxis in critically ill patients
- Trial name
- NCT04982055
- Testing
- Nadroparin (intravenous Infusion), Nadroparin (subcutaneous group)
- Volunteers
- 60 people
- Sponsor
- Clinique Saint Pierre Ottignies
Venous Thromboembolism, Urologic Cancer
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy).
- Trial name
- PREVENT-GU (NCT05920343)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Ottawa Hospital Research Institute